UK NHS Could Save £89 Million and Further the Fight Against Antimicrobial Resistance

A new study just published in the Journal of Medical Economics titled “Application of a simple point-of-care test to reduce UK healthcare costs and adverse events in outpatient acute respiratory infections” found that the FebriDx® test could save the United Kingdom’s healthcare system up to £89 million a year on unnecessary antibiotics, and further its efforts in the fight against antimicrobial resistance.

 

The FebriDx test has received HealthCanada approval, Saudi Arabia FDA clearance, Singapore HSA registration, Pakistan DRAP registration and is CE marked for sale in Europe. At this time, FebriDx has not received U.S. Food and Drug Administration (FDA) clearance and is not commercially available in the United States. For more information on FebriDx, visit febridx.com.

 

Media contact: Saranova, LLC • [email protected] • +1.941.928.9025

SEE ALSO
October 6, 2020

Lumos Diagnostics raises AU$25m in oversubscribed pre-IPO capital raise

Lumos Diagnostics has closed an oversubscribed AU$25 million pre-IPO capital raise, ahead of an anticipated 2021 Australian Securities Exchange (ASX) listing.

Reach out to Lumos today to understand how we can deliver you a customized point-of-care diagnostic solution.